Емпагліфлозин в первинній кінцевій комбінованій точці знижував відносний ризик серцево-судинної смерті та госпіталізації з приводу серцевої недостатності на 25 % у дорослих пацієнтів, з цукровим діабетом та без нього, які мали серцеву недостатність зі зни

Автор(и)

  • - - -

DOI:

https://doi.org/10.30978/CEES-2020-3-97

Ключові слова:

-

Анотація

-

Біографія автора

- -, -

-

Посилання

Packer M, Anker SD, Butler J et al. Cardiac and Renal Outcomes With Empagliflozin in Heart Failure With a Reduced Ejection Fraction. Engl J Med. 2020;10.1056/NEJMoa2022190.

Ambrosy A, Fonarow G, Butler J et al. The Global Health and Economic Burden of Hospitalizations for Heart Failure. Lessons Learned From Hospitalized Heart Failure Registries. J Am Coll Cardiol. 2014;63(12):1123–33.

Packer M. EMPEROR-Reduced: Empagliflozin in Heart Failure With a Reduced Ejection Fraction, With and Without Diabetes. Presented on 29 August 2020 at the European Society of Cardiology (ESC) Congress 2020 – The Digital Experience.

American Heart Association. What is Heart Failure? Available at: https://www.heart.org/en/health-topics/heart-failure/what-is-heart-failure. Accessed: August 2020.

Anderson JL and Morrow DA. Acute Myocardial Infarction. Engl J Med. 2017;376:2053–64.

American Heart Association. Warning Signs of Heart Failure. Available at: https://www.heart.org/en/health-topics/heart-failure/warning-signs-of-heart-failure. Accessed August 2020.

Calvert MJ, Freemantle , Cleland JGF. The impact of chronic heart failure on health‐related quality of life data acquired in the baseline phase of the CARE‐HF study. Eur J Heart Fail. 2005;7(2):243–51.

Sarnak MJ. A patient with heart failure and worsening kidney function. Clin J Am Soc ephrol. 2014;9(10):1790–98.

Boehringer Ingelheim Pharmaceuticals, Inc. Press release. 2019. https://www.boehringer-ingelheim.com/press-release/fda-fast-track-designation-chronic-heart-failure. Accessed August 2020.

ClinicalTrials.gov. EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved). Available at: https://clinicaltrials.gov/ct2/show/NCT03057951. Accessed August 2020.

ClinicalTrials.gov. EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin). Available at: https://clinicaltrials.gov/ct2/show/NCT03594110. Accessed August 2020.

Boehringer Ingelheim Pharmaceuticals, Inc. Press release. 2020. Available at: https://www.boehringer-ingelheim.com/press-release/fda-fast-track-chronic-kidney-disease. Accessed August 2020.

Boehringer Ingelheim Pharmaceuticals, Inc. Press release. 2020. Available at: https://www.boehringer-ingelheim.com/press-release/dcri-collaboration-empact-mi. Accessed August 2020.

ClinicalTrials.gov. EMPagliflozin initiated in patients hospitalised for acUte heart faiLure (de ovo or decompensated chronic HF) who have been StabilisEd (EMPULSE) Available at: https://www.clinicaltrials.gov/ct2/show/NCT04157751. Accessed August 2020.

ClinicalTrials.gov. EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced). Available at: https://clinicaltrials.gov/ct2/show/NCT03057977. Accessed August 2020.

American Heart Association. Ejection Fraction Heart Failure Measurement. Available at: https://www.heart.org/en/health-topics/heart-failure/diagnosing-heart-failure/ejection-fraction-heart-failure-measurement. Accessed: August 2020.

GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and ational life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: A systematic analysis for the Global Burden of Disease Study 2015. The Lancet. 2016; 388(10053):1459–544.

ClinicalTrials.gov. A phase III randomised, double-blind trial to evaluate the effect of 12 weeks treatment of once daily EMPagliflozin 10 mg compared with placebo on ExeRcise ability and heart failure symptoms, In patients with chronic HeArt FaiLure with reduced Ejection Fraction (HFrEF) (EMPERIAL – reduced). Available at: https://clinicaltrials.gov/ct2/show/NCT03448419. Accessed August 2020.

ClinicalTrials.gov. A phase III randomised, double-blind trial to evaluate the effect of 12 weeks treatment of once daily EMPagliflozin 10 mg compared with placebo on ExeRcise ability and heart failure symptoms, in patients with chronic HeArt FaiLure with preserved Ejection Fraction (HFpEF) (EMPERIAL – preserved). Available at: https://clinicaltrials.gov/ct2/show/NCT03448406. Accessed August 2020.

Zinman B, Wanner C, Lachin JM et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. Engl J Med. 2015;373:2117–28.

Kim DJ, Sheu WH-H, Seino Y et al. Cardiovascular Effectiveness and Safety of Empagliflozin in Routine Care in East Asia: Results from the EMPRISE study. Presented at IDF Congress 2019. 2-6 December 2019, Busan, Korea.

Patorno E, Pawar A, Franklin J et al. Empagliflozin and the risk of heart failure hospitalization in routine clinical care: a first analysis from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) Trial. Circulation. 2019;139:2822-30.

Yancy CW, Jessup M, Bozkurt B et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;128(16):e240–e327.

Suskin , McKelvie RS, Burns RJ et al. Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. Eur Heart J. 2000;21:1368–75.

Ronco C, McCullough P, Anker SD et al. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J. 2010;31(6):703–11.

Lazzeri C, Valente S, Tarquini R et al. Cardiorenal syndrome caused by heart failure with preserved ejection fraction. Int J ephrol. 2011;2011:634903.

Jardiance® (empagliflozin) tablets, U.S. Prescribing Information. Available at: http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Jardiance/jardiance.pdf. Accessed: August 2020.

Jardiance® (empagliflozin) tablets. European Product Information; approved April 2020. Available at: https://www.ema.europa.eu/en/documents/product-information/jardiance-epar-product-information_en.pdf. Accessed August 2020.

Jardiance® (Full Prescribing Information). Mexico; Boehringer Ingelheim Pharmaceuticals, Inc; 2017.

Vallon V and Thompson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia. 2017;60(2):215–25.

##submission.downloads##

Опубліковано

2020-09-30

Номер

Розділ

Новини та актуальна інформація